HealthQuill drug manufacturing expansion
Novartis AG, a global Switzerland-based pharmaceutical company, has agreed to pay Monte Rosa Therapeutics Inc., $150 million upfront to develop, manufacture and commercialise drug candidates, mainly in immunology.
Pharma

Novartis bets $23b on US as pharma giants brace for tariff storm

Swati Mishra April 11, 2025: “We are prepared for shifts in the external environment and fully confident in our growth outlook,” Novartis CEO Vas.

Read More